Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Straumann Group reports revenue exceeding CHF 2 billion
Straumann Group reports revenue exceeding CHF 2 billion
Straumann Group reports revenue exceeding CHF 2 billion
Einladung: Straumann Group Webcast - Jahresergebnisse 2021
Einladung: Straumann Group Webcast - Jahresergebnisse 2021
Einladung: Straumann Group Webcast - Jahresergebnisse 2021
Invitation: Straumann Group 2021 full-year financial results webcast
Invitation: Straumann Group 2021 full-year financial results webcast
Invitation: Straumann Group 2021 full-year financial results webcast
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021
DGAP-Adhoc: BB Biotech AG closes the 2021 fiscal year with a loss
DGAP-Adhoc: BB Biotech AG closes the 2021 fiscal year with a loss
DGAP-Adhoc: BB Biotech AG closes the 2021 fiscal year with a loss
DGAP-News: BB BIOTECH AG: 2021 war ein schwieriges Jahr für die Biotechaktienmärkte - Erhöhung der Dividende auf CHF 3.85 vorgeschlagen
DGAP-News: BB BIOTECH AG: 2021 war ein schwieriges Jahr für die Biotechaktienmärkte - Erhöhung der Dividende auf CHF 3.85 vorgeschlagen
DGAP-News: BB BIOTECH AG: 2021 war ein schwieriges Jahr für die Biotechaktienmärkte - Erhöhung der Dividende auf CHF 3.85 vorgeschlagen
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
Sonova verstärkt Präsenz auf dem US-Markt:
Akquisition einer führenden Kette von Hörakustikgeschäften
Sonova verstärkt Präsenz auf dem US-Markt: Akquisition einer führenden Kette von Hörakustikgeschäften
Sonova verstärkt Präsenz auf dem US-Markt: Akquisition einer führenden Kette von Hörakustikgeschäften
Sonova to increase presence in US market:
Acquisition of leading audiological care network
Sonova to increase presence in US market: Acquisition of leading audiological care network
Sonova to increase presence in US market: Acquisition of leading audiological care network
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Sonova nominates Julie Tay for election as a new member of
the Board of Directors
EQS-News: Sonova nominates Julie Tay for election as a new member of the Board of Directors
EQS-News: Sonova nominates Julie Tay for election as a new member of the Board of Directors
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN ENDGÜLTIGE ERGEBNISSE DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN ENDGÜLTIGE ERGEBNISSE DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN ENDGÜLTIGE ERGEBNISSE DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.
EQS-News: Straumann Group Capital Markets Day 2021
EQS-News: Straumann Group Capital Markets Day 2021
EQS-News: Straumann Group Capital Markets Day 2021
3 Stocks to Buy for a Soft Landing, If There Is One: https://www.marketbeat.com/logos/articles/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg
3 Stocks to Buy for a Soft Landing, If There Is One

Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve’s monetary policy regarding interest rates is neither too restrictive nor too

HealthEquity Stock: Leading Health Savings Account Investment: https://www.marketbeat.com/logos/articles/med_20240609114559_chart-hqy.jpg
HealthEquity Stock: Leading Health Savings Account Investment

HealthEquity Inc (NASDAQ: HQY) is one of the nation’s largest providers of health savings accounts (HSA) and consumer-directed benefits (CDB) services. Its platform enables individuals to open

Johnson & Johnson is as Cheap as it’s Going to Get: https://www.marketbeat.com/logos/articles/med_20240416075018_chart-jnj-4162024ver001.png
Johnson & Johnson is as Cheap as it’s Going to Get

Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading

S&P 500's surge to new highs: Bull trap hiding in plain sight?: https://www.marketbeat.com/logos/articles/med_20240215083237_sp-500s-surge-to-new-highs-bull-trap-hiding-in-pla.jpg
S&P 500's surge to new highs: Bull trap hiding in plain sight?

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) is trading at new highs, but as the sharp pullback on February 13 showed, the rally may be showing signs of cracking.

The market went back into rally

Med-tech stock Conmed dips ahead of big Q4 report...opportunity?: https://www.marketbeat.com/logos/articles/med_20240129182456_med-tech-stock-conmed-dips-ahead-of-big-q4-report.jpg
Med-tech stock Conmed dips ahead of big Q4 report...opportunity?

When Utica, NY-based medical technology company CONMED Corporation (NYSE:CNMD) reports fourth quarter financials after the close on Wednesday, it is expected to post some of its best growth in

HCA Healthcare Rallies: Weight-loss drugs really a big threat?: https://www.marketbeat.com/logos/articles/med_20240107185912_hca-healthcare-rallies-weight-loss-drugs-really-a.jpg
HCA Healthcare Rallies: Weight-loss drugs really a big threat?

Hospital chain HCA Healthcare, Inc. (NYSE: HCA) has been working on a bullish base and even managed to post gains in a week when the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) pulled back. 

Investors